1. HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.
- Author
-
Cioni B, Jordanova ES, Hooijberg E, van der Linden R, de Menezes RX, Tan K, Willems S, Elbers JBW, Broeks A, Bergman AM, Zuur CL, and de Boer JP
- Subjects
- Aged, B7-H1 Antigen metabolism, Cohort Studies, Disease-Free Survival, Female, Histocompatibility Antigens Class I metabolism, Humans, Macrophages, Male, Middle Aged, Oropharyngeal Neoplasms mortality, Oropharyngeal Neoplasms therapy, Papillomaviridae, Papillomavirus Infections metabolism, Papillomavirus Infections pathology, Programmed Cell Death 1 Receptor metabolism, Retrospective Studies, Survival Rate, Treatment Outcome, Tumor Microenvironment, HLA-D Antigens metabolism, Oropharyngeal Neoplasms metabolism
- Abstract
Background: Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV-positive OPSCC patient., Methods: A comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD-L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients., Results: We found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor-associated macrophages (TAMs). High HLA-DP/DQ/DR expression and low number of TAMs were associated with longer disease-specific survival and disease-free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis., Conclusions: \We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy., (© 2018 The Authors. Head & Neck published by Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF